CenterBook Partners’s Sarepta Therapeutics SRPT Stock Holding History

CenterBook Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.8M	Buy	153,853 +107,560	+232%	+$2.01M	0.13%	204
2026 Q2	$832K	Buy	+46,293	New	+$876K	0.04%	396
2025 Q2	–	Sell	-4,397	Closed	-$281K	–	593
2025 Q1	$281K	Buy	+4,397	New	+$463K	0.02%	456
2023 Q3	–	Sell	-6,054	Closed	-$693K	–	494
2023 Q2	$693K	Buy	+6,054	New	+$781K	0.09%	296

Other funds holding SRPT

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $45.4B AUM 34.02% 1-Year Est. Return

CenterBook Partners's SRPT Position: Q3 2026 in Review

CenterBook Partners increased its Sarepta Therapeutics (SRPT) stake by 232% in Q3 2026, buying an estimated $2.01M and bringing the position to 153,853 shares worth $2.8M. The position accounts for 0.13% of the portfolio, ranked #204.

CenterBook Partners first reported a position in SRPT in Q2 2023 and has held it in 4 quarters since. 159 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

CenterBook Partners held 153,853 shares of Sarepta Therapeutics worth $2.8M as of Q3 2026.
CenterBook Partners bought 107,560 Sarepta Therapeutics shares in Q3 2026, an estimated $2.01M.
Sarepta Therapeutics made up 0.13% of CenterBook Partners's portfolio in Q3 2026, its #204 holding.
CenterBook Partners first reported a position in Sarepta Therapeutics in Q2 2023 and has held it in 4 quarters since.
159 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on CenterBook Partners's 13F filing for Q3 2026, filed 2 Nov 2026.